Trial · NCT04836559
Results by group374
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 374
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Cohort 1 and 2: Time to Baseline Monthly Seizure Count up to the End of the 12-week Double-blind (DB) Treatment Period | DB: Cohort 1: Placebo | 32 | 95% Confidence Interval 28 to 37 | Days | |
| Cohort 1 and 2: Time to Baseline Monthly Seizure Count up to the End of the 12-week Double-blind (DB) Treatment Period | DB: Cohort 1: JNJ-40411813 | 34 | 95% Confidence Interval 27 to 48 | Days | |
| Cohort 1 and 2: Time to Baseline Monthly Seizure Count up to the End of the 12-week Double-blind (DB) Treatment Period | DB: Cohort 2: Placebo | 29 | 95% Confidence Interval 22 to 69 | Days | |
| Cohort 1 and 2: Time to Baseline Monthly Seizure Count up to the End of the 12-week Double-blind (DB) Treatment Period | DB: Cohort 2: JNJ-40411813 | 38 | 95% Confidence Interval 28 to 48 | Days | |
| Cohort 1 and 2: Percent Reduction in the Open Label Extension (OLE) Period Monthly Seizure Rate | OLE: Cohort 1: Placebo Followed by JNJ-40411813 | 39.9 | Inter-Quartile Range 14.3 to 64.1 | Percent change (reduction) | |
| Cohort 1 and 2: Percent Reduction in the Open Label Extension (OLE) Period Monthly Seizure Rate | OLE: Cohort 1: JNJ-40411813 Followed by JNJ-40411813 | 49.1 | Inter-Quartile Range -1.5 to 77.1 | Percent change (reduction) | |
| Cohort 1 and 2: Percent Reduction in the Open Label Extension (OLE) Period Monthly Seizure Rate | OLE: Cohort 2: Placebo Followed by JNJ-40411813 | 29.1 | Inter-Quartile Range 22.6 to 76.6 | Percent change (reduction) | |
| Cohort 1 and 2: Percent Reduction in the Open Label Extension (OLE) Period Monthly Seizure Rate | OLE: Cohort 2: JNJ-40411813 Followed by JNJ-40411813 | 52.1 | Inter-Quartile Range -3.7 to 85.0 | Percent change (reduction) | |
| Cohort 1 and 2: Number of Participants With Seizure Freedom at the End of OLE Period | OLE: Cohort 1: Placebo Followed by JNJ-40411813 | 1 | 14.3 to 64.1 | Participants | |
| Cohort 1 and 2: Number of Participants With Seizure Freedom at the End of OLE Period | OLE: Cohort 1: JNJ-40411813 Followed by JNJ-40411813 | 0 | -1.5 to 77.1 | Participants | |
| Cohort 1 and 2: Number of Participants With Seizure Freedom at the End of OLE Period | OLE: Cohort 2: Placebo Followed by JNJ-40411813 | 0 | 22.6 to 76.6 | Participants | |
| Cohort 1 and 2: Number of Participants With Seizure Freedom at the End of OLE Period | OLE: Cohort 2: JNJ-40411813 Followed by JNJ-40411813 | 3 | -3.7 to 85.0 | Participants | |
| Cohort 1 and 2: Number of Participants With at Least 50 Percent (%) Reduction (Response) in the OLE Monthly Seizure Count | OLE: Cohort 1: Placebo Followed by JNJ-40411813 | 5 | Participants | ||
| Cohort 1 and 2: Number of Participants With at Least 50 Percent (%) Reduction (Response) in the OLE Monthly Seizure Count | OLE: Cohort 1: JNJ-40411813 Followed by JNJ-40411813 | 11 | Participants | ||
| Cohort 1 and 2: Number of Participants With at Least 50 Percent (%) Reduction (Response) in the OLE Monthly Seizure Count | OLE: Cohort 2: Placebo Followed by JNJ-40411813 | 3 | Participants | ||
| Cohort 1 and 2: Number of Participants With at Least 50 Percent (%) Reduction (Response) in the OLE Monthly Seizure Count | OLE: Cohort 2: JNJ-40411813 Followed by JNJ-40411813 | 16 | Participants | ||
| OLE Period: Cohort 1 and 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | OLE: Cohort 1: Placebo Followed by JNJ-40411813 | TEAEs | 6 | Participants | |
| OLE Period: Cohort 1 and 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | OLE: Cohort 1: JNJ-40411813 Followed by JNJ-40411813 | TEAEs | 16 | Participants | |
| OLE Period: Cohort 1 and 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | OLE: Cohort 2: Placebo Followed by JNJ-40411813 | TEAEs | 6 | Participants | |
| OLE Period: Cohort 1 and 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | OLE: Cohort 2: JNJ-40411813 Followed by JNJ-40411813 | TEAEs | 17 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04836559/results